An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Geron (GERN) reported granting non-statutory stock options to purchase 243,000 shares of Geron common stock as inducements to newly hired employees. The options were granted at an exercise price of $3.68 per share and have a 10-year term, vesting over four years. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
Geron (GERN) ha conferito opzioni azionarie non statutarie per l'acquisto di 243.000 azioni ordinarie di Geron come incentivo ai nuovi dipendenti assunti. Le opzioni sono state concesse a un prezzo di esercizio di $3,68 per azione e hanno una durata di 10 anni, con maturazione distribuita su quattro anni. Le opzioni sono state concesse in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) e il Piano di Premi di Induzione 2018 di Geron.
Geron (GERN) ha reportado la concesión de opciones sobre acciones no estatutarias para comprar 243,000 acciones comunes de Geron como incentivos para empleados recién contratados. Las opciones se otorgaron a un precio de ejercicio de $3.68 por acción y tienen un término de 10 años, con una adquisición de derechos a lo largo de cuatro años. Las opciones se concedieron de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4) y el Plan de Premios de Inducción de 2018 de Geron.
Geron (GERN)은 신규 채용된 직원들에게 인센티브로 Geron 보통주 243,000주를 매입할 수 있는 비법적 주식 옵션을 부여했습니다. 옵션은 주당 $3.68의 행사 가격으로 부여되었으며, 10년의 기간 동안 4년에 걸쳐 권리가 확립됩니다. 옵션은 나스닥 상장 규칙 5635(c)(4) 및 Geron 2018 유인 상 플랜에 따라 부여되었습니다.
Geron (GERN) a rapporté avoir accordé des options d'achat d'actions non statutaires pour l'achat de 243 000 actions ordinaires de Geron en tant qu'incitations à de nouveaux employés recrutés. Les options ont été accordées à un prix d'exercice de $3,68 par action et ont une durée de dix ans, avec une acquisition des droits étalée sur quatre ans. Les options ont été accordées conformément à la Règle de Cotation Nasdaq 5635(c)(4) et au Plan de Prix d'Incitation de 2018 de Geron.
Geron (GERN) hat die Gewährung von nicht-gesetzlichen Aktienoptionen zum Kauf von 243.000 Stammaktien von Geron als Anreiz für neu eingestellte Mitarbeiter gemeldet. Die Optionen wurden zu einem Ausübungspreis von $3,68 pro Aktie vergeben und haben eine Laufzeit von 10 Jahren mit einer Vesting-Periode über vier Jahre. Die Optionen wurden gemäß der Nasdaq Listing Rule 5635(c)(4) und dem Geron 2018 Inducement Award Plan gewährt.
Positive
None.
Negative
None.
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
The stock options were granted on April 17, 2024, at an exercise price of $3.68 per share, which is equal to the closing price of Geron common stock on the date of grant. The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. All of the stock options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018, and provides for the granting of stock options to new employees.
About Geron
Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat for the treatment of transfusion dependent anemia in adult patients with lower risk myelodysplastic syndromes (LR MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. In addition, an MAA is under review in the European Union for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (MF). To learn more, visit www.geron.com or follow us on LinkedIn.
How many shares of Geron common stock were granted as inducements to newly hired employees?
Geron granted 243,000 shares of Geron common stock as inducements to newly hired employees.
What is the exercise price of the stock options granted by Geron?
The exercise price of the stock options granted by Geron is $3.68 per share.
Under what Nasdaq listing rule were the stock options granted?
The stock options were granted under Nasdaq Listing Rule 5635(c)(4) by Geron.
What is the term of the stock options granted by Geron?
The stock options granted by Geron have a 10-year term.
How do the stock options vest for the newly hired employees?
The stock options vest over four years, with 12.5% of the shares vesting on the six-month anniversary of employment and the remaining shares vesting over the following 42 months.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
